Incyte (INCY) agreed to acquire Star Therapeutics unit Vega Therapeutics in a deal worth up to $2 billion, expanding its hematology portfolio into bleeding disorders.
Star Therapeutics will receive $1.25 billion upfront, with up to $750 million in milestones payments, biopharmaceutical company Incyte said Monday.
Vega Therapeutics' lead candidate, VGA039, improves hemostasis that helps control blood loss in bleeding disorders, Incyte said. The investigational drug is currently in a late-stage trial for patients with von Willebrand disease, the most common inherited bleeding disorder.
"VGA039 fits directly into our strategy of building a top-tier growth company for the future," Incyte Chief Executive Bill Meury said in a statement. "It is a first-in-class, phase 3 asset with compelling early data, a manageable development path and the potential to become an important new growth driver in one of our core therapeutic areas -- hematology."
The transaction is expected to close in the third quarter.
"VGA039 will be advanced by Incyte," Star Therapeutics CEO Adam Rosenthal said.
Incyte expects the Hart-Scott-Rodino review to result in a research-and-development charge of about $1.25 billion in third-quarter and full-year results.
Price: $103.24, Change: $+0.86, Percent Change: +0.84%



